Funding Details
- Awarder
- SOSV
- Date Award
- June 10, 2024
- Vertical
- Biopharma
- Funding URL
- View Funding Page
Company Info
- Founders
- Poulami Chaudhuri, Rohini Kalvakuntla, Anirudh Nishtala
- Company Description
- Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure™ 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.
- Market
- Human Health
- Location
-
United States
Links